Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in children: A randomized controlled trial

Clinical Infectious Diseases

Volumn 34, Issue 2, 2002, Pages 154-158

  Cascio, Antonio ^a   Colomba, Claudia ^a   Antinori, Spinello ^a   Paterson, David L ^b   Titone, Lucina ^a  

^a Ospedale dei Bambini G Di Cristina   (Italy)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CHLORAMPHENICOL; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; JOSAMYCIN; ROXITHROMYCIN; TETRACYCLINE DERIVATIVE;

ADOLESCENT; APLASTIC ANEMIA; ARTICLE; BOUTONNEUSE FEVER; CHILD; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMOLYTIC ANEMIA; HUMAN; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RICKETTSIOSIS;

ADOLESCENT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BOUTONNEUSE FEVER; CHILD; CHILD, PRESCHOOL; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; MALE; RICKETTSIA CONORII; TREATMENT OUTCOME;

EID: 0037079862     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/338068     Document Type: Article

References (31)

1. Clinical and laboratory findings of boutonneuse fever in Sicilian children
2. Relationships between the Rhipicephalus sanguineus complex ecology and Mediterranean spotted fever epidemiology in France
3. Rickettsioses as paradigms of new emerging infectious diseases
4. Resurgence of Mediterranean spotted fever
5. Widespread simultaneous increase in the incidence of spotted fever group rickettsioses
6. Climatic factors in resurgence of Mediterranean spotted fever
7. Epidemiology of rickettsial diseases
8. Boutonneuse fever in American travellers
9. Imported rickettsial disease: Clinical and epidemiological features
10. Mediterranean spotted fever in an American woman
11. Rickettsiosi
12. Rickettsioses
13. Requiem for tetracycline
14. Rickettsia rickettsii and other spotted fever group rickettsiae (Rocky Mountain spotted fever and other spotted fevers)
15. G6PD deficiency and haemolytic anemia
16. The "gray toddler": Chloramphenicol toxicity
17. Statewide study of chloramphenicol therapy and fatal aplastic anemia
18. In vitro susceptibilities of Rickettsia and Bartonella spp. to 14-hydroxy-clarithromycin as determined by immunofluorescent antibody analysis of infected Vero cell monolayers
19. In vitro susceptibilities of Bartonella henselae, B. quintana, B. elizabethae, Rickettsia rickettsii, R. conorii, R. akari, and R. prowazekii to macrolide antibiotics as determined by immunofluorescent-antibody analysis of infected Vero cell monolayers
20. In vitro susceptibilities of spotted fever group Rickettsiae and Coxiella burnetii to clarithromycin
21. In vitro susceptibilities of Rickettsia rickettsii and Rickettsia conorii to roxithromycin and pristinamycin
22. In vitro evaluation of josamycin, spiramycin, and erythromycin against Rickettsia rickettsi and R. conorii
23. The invitro anti-rickettsial activity of macrolides
24. In vitro susceptibilities of 27 Rickettsiae to 13 antimicrobials
25. In vitro antibiotic susceptibility of Rickettsia rickettsii and Rickettsia conorii: Plaque assay and microplaque colorimetric assay
26. Mediterranean spotted fever in Marseille: Descriptive epidemiology and the influence of climatic factors
27. Efficacy and safety of clarithromycin in the treatment of Mediterranean spotted fever in children: A randomized controlled trial
28. Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions
29. Erythromycin versus tetracycline for treatment of Mediterranean spotted fever
30. Azithromycin vs doxycycline for Mediterranean spotted fever
31. Randomized trial of doxycycline versus josamycin for Mediterranean spotted fever